What is the recommended dosing regimen and safety monitoring for Tremfya (guselkumab) in an adult with moderate‑to‑severe plaque psoriasis who has failed topical therapy or phototherapy?

Tremfya (Guselkumab) for Moderate-to-Severe Plaque Psoriasis

Administer Tremfya 100 mg by subcutaneous injection at week 0, week 4, and then every 8 weeks thereafter. This is the FDA-approved dosing regimen with strong guideline support and can be self-administered after proper training 1.

Dosing Regimen

The standard dosing is straightforward and evidence-based:

• Initial loading: 100 mg subcutaneous injection at week 0 and week 4
• Maintenance: 100 mg every 8 weeks thereafter 2

This regimen received a Grade A recommendation from the joint AAD-NPF guidelines 2. The dosing schedule offers a significant convenience advantage over many other biologics, requiring only 7 injections in the first year.

Administration Details

• Allow the medication to reach room temperature for 30 minutes before injection (do not remove needle cap during warming) 1
• Inject into front of thighs, lower abdomen (avoiding 2 inches around navel), or back of upper arms (healthcare provider/caregiver only)
• Avoid areas where skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis 1
• If a dose is missed: Administer as soon as possible, then resume the regular schedule 1

Pre-Treatment Evaluation

Before initiating Tremfya, complete these mandatory assessments:

• Tuberculosis screening: Evaluate all patients for TB infection prior to treatment 1
• Vaccinations: Complete all age-appropriate immunizations according to current guidelines before starting therapy 1
• Avoid live vaccines once treatment begins 1

Efficacy Expectations

Tremfya demonstrates superior efficacy compared to other biologics:

• At week 16, 70% of patients achieved PASI 90 (vs 46.8% with adalimumab and 2.4% with placebo) in the VOYAGE 2 trial 2
• 73.3% achieved PASI 90 at week 16 in VOYAGE 1 (vs 49.7% with adalimumab) 3
• Approximately one-third achieve complete clearance (PASI 100) 2

Response Timeline

• Assess treatment response at 12 weeks of continuous therapy 2
• If partial response at 12 weeks, consider adding topical corticosteroids, vitamin D analogues, methotrexate, or UVB phototherapy 2
• Although no published data support combination therapy with IL-23 inhibitors, there is no reason to consider it unsafe 2

Safety Monitoring

Common Adverse Events

The most frequently reported adverse events (≥1%) include 1:

• Upper respiratory infections
• Headache
• Injection site reactions
• Arthralgia
• Bronchitis
• Diarrhea
• Gastroenteritis
• Tinea infections
• Herpes simplex infections

Long-Term Safety Profile

Extensive safety data from 2,891 patients followed for up to 5 years (8,662 patient-years) demonstrates 4:

• No cases of Crohn's disease, ulcerative colitis, opportunistic infections, or active tuberculosis
• Serious infection rate: 0.9 per 100 patient-years
• Malignancy rate: 0.7 per 100 patient-years
• Major adverse cardiovascular events: 0.3 per 100 patient-years

Specific Precautions

• Active infections: Do not initiate treatment during clinically important active infections; discontinue if serious infection develops 1
• Immunosuppression: Use caution in patients with pre-existing immunosuppression-related conditions 2
• Temporary discontinuation: Consider holding treatment during febrile illness requiring antibiotics; restart after full resolution and completion of antibiotic course 2

Contraindications

Do not use in patients with serious hypersensitivity reactions to guselkumab or any excipients 1.

Special Populations

• Pregnancy/Lactation: No human pregnancy studies exist; animal studies showed no harm to developing fetus 2
• Psoriatic arthritis: Tremfya is also FDA-approved for active psoriatic arthritis at the same dosing regimen 1
• Scalp, nail, and palmoplantar psoriasis: Grade A recommendation for these specific manifestations 2

Treatment Failure Management

If inadequate response after 12 weeks:

• Primary failure to one biologic does not preclude response to Tremfya 2
• Tremfya successfully treats patients with incomplete responses to adalimumab (66.1% achieved PASI 90 at week 48 after switching) 2
• Also effective in patients inadequately responding to ustekinumab 2

Retreatment After Interruption

If treatment is interrupted, consider repeating loading doses (week 0 and week 4) if:

• The patient is experiencing a flare, OR
• More than 3-4 half-lives have passed since the previous dose 2

The necessity depends on disease severity and number of missed doses 2.

Key Clinical Advantages

• Convenient dosing: Every 8 weeks after initial loading (less frequent than most biologics)
• Self-administration: Patients can inject at home after training 1
• Superior efficacy: Outperforms adalimumab and demonstrates high PASI 90/100 rates 2, 3
• Favorable safety profile: No increased risk of serious infections, malignancy, or inflammatory bowel disease through 5 years of follow-up 4
• Consistent across populations: Effective regardless of prior biologic exposure, age, BMI, or sex 5